Overcoming resistance to αPD-1 of MMR-deficient tumors with high tumor-induced neutrophils levels by combination of αCTLA-4 and αPD-1 blockers

BACKGROUND: Clinical studies have highlighted the efficacy of anti-programmed death 1 (αPD-1) monoclonal antibodies in patients with DNA mismatch repair-deficient (MMRD) tumors. However, the responsiveness of MMRD cancers to αPD-1 therapy is highly heterogeneous, and the origins of this variability...

Descripción completa

Detalles Bibliográficos
Autores principales: Nebot-Bral, Laetitia, Hollebecque, Antoine, Yurchenko, Andrey A, de Forceville, Louise, Danjou, Mathieu, Jouniaux, Jean-Mehdi, Rosa, Reginaldo C A, Pouvelle, Caroline, Aoufouchi, Said, Vuagnat, Perrine, Smolenschi, Cristina, Colomba, Emeline, Leary, Alexandra, Marabelle, Aurelien, Scoazec, Jean-Yves, Cassard, Lydie, Nikolaev, Sergey, Chaput, Nathalie, Kannouche, Patricia
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2022
Materias:
Clinical/Translational Cancer Immunotherapy
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9335020/
https://www.ncbi.nlm.nih.gov/pubmed/35896284
http://dx.doi.org/10.1136/jitc-2022-005059

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9335020/
https://www.ncbi.nlm.nih.gov/pubmed/35896284
http://dx.doi.org/10.1136/jitc-2022-005059

Ejemplares similares